|
|
|
|
USP’s new elastomeric packaging standards shift testing to full system‑level evaluation, strengthen integrity and usability expectations, and place compliance responsibility on drug developers.
|
|
|
|
|
See why it's important to partner with a CDMO that’s investing in advanced sterile fill-finish capabilities to meet the demands of complex biologics, gene therapies, and mRNA-based products.
|
|
|
|
|
Early‑phase programs require flexible, technically aligned fill‑finish partners. Mid‑sized CDMOs offer a balance of agility, infrastructure, and regulatory maturity suited to Phase I–II needs.
|
|
|
|
|
USP 382 introduces holistic packaging evaluation, focusing on container closure integrity, functionality, and real-world conditions to ensure sterility, safety, and product reliability.
|
|
|
|
|
|
|
Our experts and investment in state-of-the-art development and manufacturing facilities underscore our commitment to advancing programs from the clinic to commercialization.
|
|
|
|
|
|
|
Whether you are navigating technical hurdles, scaling production, or preparing for market launch, our integrated approach ensures a seamless path from bench to bedside.
|
|
|
